Stockholm, April 22 2013 — NASDAQ OMX (NASDAQ: NDAQ) announces that the trading in Immunicum AB (short name: IMMU) shares will commence today on First North at NASDAQ OMX Stockholm. Immunicum belongs to the Healthcare sector and is the fifth new company to be admitted to trading on First North in 2013.
Immunicum develops cancer immunotherapies. The company’s two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX™, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Since the raw material consists of white blood cells (DCs) from healthy donors, Immunicum’s products can be produced in large scale. For more information, visit www.immunicum.se.
“This is an exciting day for Immunicum and we welcome the nearly 900 new shareholders that participated in the IPO,” said Jamal El-Mosleh, CEO at Immunicum. “At First North we aim to gain increased exposure for our unique products by reaching out to a wider investor audience. Now we look forward to leveraging our publicly traded status in order to build our brand and support continued financial growth to our shareholders.”
“We congratulate Immunicum on their oversubscribed IPO and welcome them to First North and our healthcare sector,” said Emelie Jarnesten, head of NASDAQ OMX First North. “First North continues to be successful in attracting entrepreneurial growth companies and we welcome more companies to take advantage of the investor visibility and reach that we can offer.”
Immunicum has appointed G&W Fondkommission as Certified Adviser.
To view a CEO video interview with Immunicum click here.
About First North
First North is regulated as a multilateral trading facility, operated by the different exchanges within NASDAQ OMX Nordic. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.
About NASDAQ OMX
The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 24 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.999% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (http://www.facebook.com/NASDAQ) and Twitter (http://www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500)
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about NASDAQ OMX's products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
+46 8 405 66 39